CTLA4 and melanoma: In melanoma patients who have progressed on anti-CTLA-4 therapy and subsequently treated with anti-PD-1 (n = 35), an increase in the number of unique CDR3 sequences (richness) was associated with clinical benefit (Riaz et al. 2017).